Lantheus (LNTH) said Monday it has received a tentative approval from the US Food and Drug Administration for its abbreviated new drug application for PNT2003, a radioequivalent to lutathera.
Full approval is subject to the expiration of a 30-month stay in June to Hatch-Waxman patent litigation, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.